MiMedx Group Inc  

(Public, NASDAQ:MDXG)   Watch this stock  
Find more results for MDXG
+0.40 (4.30%)
After Hours: 9.70 0.00 (0.00%)
Mar 28, 4:38PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.17 - 9.70
52 week 6.64 - 10.02
Open 9.32
Vol / Avg. 0.00/862,452.00
Mkt cap 1.08B
P/E 91.28
Div/yield     -
EPS 0.11
Shares 108.84M
Beta 0.96
Inst. own 52%
Feb 21, 2017
Q4 2016 MiMedx Group Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 7.84% 4.89%
Operating margin 12.47% 7.53%
EBITD margin - 9.76%
Return on average assets 11.73% 7.28%
Return on average equity 17.16% 9.94%
Employees 690 -
CDP Score - -


1775 W Oak Commons Ct
MARIETTA, GA 30062-2254
United States - Map
+1-678-3846720 (Phone)
+1-678-3846720 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.

Officers and directors

Parker H. Petit Jr. Chairman of the Board, Chief Executive Officer
Age: 75
Bio & Compensation  - Reuters
William Charles Taylor President, Chief Operating Officer, Director
Age: 47
Bio & Compensation  - Reuters
Michael J. Senken Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Alexandra O. Haden General Counsel, Secretary
Age: 40
Bio & Compensation  - Reuters
Charles E. Koob Director
Age: 70
Bio & Compensation  - Reuters
Luis A. Aguilar Independent Director
Age: 64
Bio & Compensation  - Reuters
Joseph G. Bleser Independent Director
Age: 69
Bio & Compensation  - Reuters
J. Terry Dewberry Independent Director
Bio & Compensation  - Reuters
Charles R. Evans Independent Director
Age: 68
Bio & Compensation  - Reuters